United Therapeutics (UTHR)

• Market cap: $18.5B
• 1 day: 1.12%
• 5 days: 1.68%
• 1 month: 29.96%
• 3 months: 39.93%
• 6 months: 29.95%
• Year to date: 13.32%
• 1 year: 19.15%
• 5 years: 286.21%
• 10 years: 170.84%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Employees: 1,305

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 279 | Existing positions reduced: 215

28% more call options, than puts

Call options by funds: $134M | Put options by funds: $105M

10% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 70

0% less funds holding

Funds holding: 662 [Q1] → 661 (-1) [Q2]

1.63% less ownership

Funds ownership: 98.82% [Q1] → 97.19% (-1.63%) [Q2]

8% less capital invested

Capital invested by funds: $13.7B [Q1] → $12.6B (-$1.08B) [Q2]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q1] → 9 (-1) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $328
• Avg. target: $473
• High target: $575

9 analyst ratings

• positive: 6 67%
• neutral: 3 33%
• negative: 0 0%

Cantor Fitzgerald Olivia Brayer	$525	Overweight Maintained	10 Sep 2025
Oppenheimer Andreas Argyrides	$575	Outperform Maintained	5 Sep 2025
HC Wainwright & Co. Andrew Fein	$500	Buy Maintained	5 Sep 2025
UBS Ashwani Verma	$560	Buy Maintained	4 Sep 2025
Wells Fargo Tiago Fauth	$414	Equal-Weight Maintained	3 Sep 2025